US FDA drops controversial sections from its final 510(k) medtech guidance on substantial equivalence
This article was originally published in SRA
The US Food and Drug Administration has finalized much-awaited guidance on how it determines that a medical device is "substantially equivalent" to a previous legally marketed device (also known as a predicate device) under its pre-market notification or 510(k) program1,2. The most controversial sections in the guidance, on the special and abbreviated 510(k) programs, have been deliberately left out and will be tackled by the agency in a separate document later.
You may also be interested in...
Two 510(k) pilots from US FDA indicate the agency's desire for faster, easier clearances. But some observers aren’t sure if they’ll lead to real improvements.
A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.